https://orcid.org/0000-0002-8682-4419
References
- Crigler JF Jr., Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics. 1952;10(2):169–180.
- Bosma PJ, Seppen J, Goldhoorn B, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem. 1994;269(27):17960–17964.
- Aronson SJ, Junge N, Trabelsi M, et al. Disease burden and management of Crigler-Najjar syndrome: report of a world registry. Liver Int. 2022;42(7):1593–1604.
- Yohannan MD, Terry HJ, Littlewood JM. Long term phototherapy in Crigler-Najjar syndrome. Arch Dis Child. 1983;58(6):460–462.
- Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57(3):675–688.
- Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med. 2020;382(1):29–40.
- Seppen J, Bakker C, de Jong B, et al. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol Ther. 2006;13(6):1085–1092.
- Ronzitti G, Bortolussi G, van Dijk R, et al. A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome. Mol Ther Methods Clin Dev. 2016;3:16049.
- Collaud F, Bortolussi G, Guianvarc’h L, et al. Preclinical development of an AAV8-hUGT1A1 vector for the treatment of Crigler-Najjar syndrome. Mol Ther Methods Clin Dev. 2019;12:157–174.
- Bortolussi G, Zentillin L, Vanikova J, et al. Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar syndrome. Hum Gene Ther. 2014;25(9):844–855.
- D’Antiga UB L, Brunetti-Pierri N, Baumann U, et al. Adeno-associated virus vector mediated gene therapy for Crigler Najjar syndrome: preliminary report of safety and efficacy from the CareCN clinical trial. J Hepatol. 2021;75:S202.
- Aronson SJ, Veron P, Collaud F, et al. Prevalence and relevance of pre-existing anti-adeno-associated virus immunity in the context of gene Therapy for Crigler-Najjar syndrome. Hum Gene Ther. 2019;30(10):1297–1305.
- Gross DA, Tedesco N, Leborgne C, et al. Overcoming the challenges imposed by humoral immunity to AAV Vectors to achieve safe and efficient gene transfer in seropositive patients. Front Immunol. 2022;13:857276.
- Leborgne C, Barbon E, Alexander JM, et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020;26(7):1096–1101.
- Brunetti-Pierri N, Ferla R, Ginocchio VM, et al. Liver-directed adeno-associated virus mediated gene therapy for mucopolysaccharidosis type VI. NEJM Evid. 2022;1(7).
- Shi X, Aronson SJ, Ten Bloemendaal L, et al. Efficacy of AAV8-hUGT1A1 with Rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNs patients. Mol Ther Methods Clin Dev. 2021;20:287–297.